BR112015018213A2 - método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente - Google Patents
método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um pacienteInfo
- Publication number
- BR112015018213A2 BR112015018213A2 BR112015018213A BR112015018213A BR112015018213A2 BR 112015018213 A2 BR112015018213 A2 BR 112015018213A2 BR 112015018213 A BR112015018213 A BR 112015018213A BR 112015018213 A BR112015018213 A BR 112015018213A BR 112015018213 A2 BR112015018213 A2 BR 112015018213A2
- Authority
- BR
- Brazil
- Prior art keywords
- ards
- monitoring
- development
- patient
- biomarkers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
Abstract
resumo patente de invenção: "método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente". a presente invenção refere-se aos métodos para o monitoramento do desenvolvimento de e para o tratamento da ards em um paciente. o método para o monitoramento do desenvolvimento da ards é baseado na comparação do nível ou da atividade dos biomarcadores obtidos em uma amostra retirada em um ponto de tempo posterior aos níveis ou atividades dos mesmos biomarcadores em uma amostra retirada em um ponto de tempo anterior. a invenção diz respeito a outro método para determinação simultânea de um múltiplo de biomarcadores em uma amostra de um paciente, onde os referidos biomarcadores estão relacionados à ards. o nível ou a atividade dos biomarcadores é determinado. a invenção também diz respeito a um kit diagnóstico útil para a realização do método, particularmente um kit compreende um chip, tal como, um microarranjo adequado para uso na tecnologia do biochip.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20130049 | 2013-02-14 | ||
| FI20130049 | 2013-02-14 | ||
| PCT/FI2014/050051 WO2014125164A1 (en) | 2013-02-14 | 2014-01-22 | A method for determining acute respiratory distress syndrome (ards) related biomarkers, a method to monitor the development and treatment of ards in a patient |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015018213A2 true BR112015018213A2 (pt) | 2017-07-18 |
| BR112015018213A8 BR112015018213A8 (pt) | 2019-11-05 |
| BR112015018213B1 BR112015018213B1 (pt) | 2022-12-20 |
Family
ID=51353514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015018213-5A BR112015018213B1 (pt) | 2013-02-14 | 2014-01-22 | Métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10247730B2 (pt) |
| EP (1) | EP2956772B1 (pt) |
| JP (1) | JP6337020B2 (pt) |
| KR (1) | KR102121369B1 (pt) |
| CN (1) | CN105164535B (pt) |
| AU (1) | AU2014217753B2 (pt) |
| BR (1) | BR112015018213B1 (pt) |
| CA (1) | CA2898111C (pt) |
| DK (1) | DK2956772T3 (pt) |
| ES (1) | ES2683854T3 (pt) |
| HK (2) | HK1218954A1 (pt) |
| HU (1) | HUE038959T2 (pt) |
| LT (1) | LT2956772T (pt) |
| PL (1) | PL2956772T3 (pt) |
| PT (1) | PT2956772T (pt) |
| SI (1) | SI2956772T1 (pt) |
| WO (1) | WO2014125164A1 (pt) |
| ZA (1) | ZA201505386B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101451357B1 (ko) * | 2011-02-18 | 2014-10-15 | 주식회사 스템디알 | Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물 |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017171293A1 (ko) | 2016-03-31 | 2017-10-05 | (주) 인텍플러스 | 광산화 증폭을 이용한 고감도 바이오마커 정량 방법 |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| WO2018204509A1 (en) * | 2017-05-02 | 2018-11-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Predictive factors for acute respiratory distress syndrome |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| AU2019252795A1 (en) * | 2018-04-12 | 2020-10-29 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
| WO2021250267A1 (en) * | 2020-06-11 | 2021-12-16 | Scailyte Ag | A method for early detection of propensity to severe clinical manifestations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190872B1 (en) * | 1994-05-06 | 2001-02-20 | Gus J. Slotman | Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method |
| JP2002220343A (ja) * | 2001-01-26 | 2002-08-09 | Toray Ind Inc | びまん性肺疾患延命剤 |
| AU2002353934A1 (en) * | 2001-10-31 | 2003-05-12 | Oxford Glycosciences (Uk) Ltd. | Biomarkers of liver function |
| US20040072237A1 (en) * | 2001-12-26 | 2004-04-15 | Barry Schweitzer | Use of cytokines secreted by dendritic cells |
| GB0414798D0 (en) * | 2004-07-01 | 2004-08-04 | Paradigm Therapeutics Ltd | Receptor |
| WO2006039819A1 (en) * | 2004-10-15 | 2006-04-20 | St. Michael's Hospital | Markers of lung injury |
| EP1907421A4 (en) * | 2005-06-30 | 2012-03-28 | Abbott Lab | IL-12 / P40 BINDING PROTEINS |
| DE102006046411A1 (de) * | 2006-09-20 | 2008-03-27 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von akutem Lungenversagen (ALI) |
| FI20070795A0 (fi) * | 2007-10-24 | 2007-10-24 | Faron Pharmaceuticals Oy | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| JP6012473B2 (ja) * | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
-
2014
- 2014-01-22 LT LTEP14752032.4T patent/LT2956772T/lt unknown
- 2014-01-22 CA CA2898111A patent/CA2898111C/en active Active
- 2014-01-22 HU HUE14752032A patent/HUE038959T2/hu unknown
- 2014-01-22 WO PCT/FI2014/050051 patent/WO2014125164A1/en active Application Filing
- 2014-01-22 ES ES14752032.4T patent/ES2683854T3/es active Active
- 2014-01-22 CN CN201480008939.0A patent/CN105164535B/zh active Active
- 2014-01-22 PT PT14752032T patent/PT2956772T/pt unknown
- 2014-01-22 AU AU2014217753A patent/AU2014217753B2/en active Active
- 2014-01-22 EP EP14752032.4A patent/EP2956772B1/en active Active
- 2014-01-22 KR KR1020157019483A patent/KR102121369B1/ko active IP Right Grant
- 2014-01-22 DK DK14752032.4T patent/DK2956772T3/en active
- 2014-01-22 JP JP2015557488A patent/JP6337020B2/ja active Active
- 2014-01-22 BR BR112015018213-5A patent/BR112015018213B1/pt active IP Right Grant
- 2014-01-22 SI SI201430802T patent/SI2956772T1/sl unknown
- 2014-01-22 US US14/767,464 patent/US10247730B2/en active Active
- 2014-01-22 PL PL14752032T patent/PL2956772T3/pl unknown
-
2015
- 2015-07-27 ZA ZA2015/05386A patent/ZA201505386B/en unknown
-
2016
- 2016-06-15 HK HK16106861.5A patent/HK1218954A1/zh unknown
- 2016-06-21 HK HK16107094.2A patent/HK1219130A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE038959T2 (hu) | 2018-12-28 |
| CA2898111C (en) | 2022-02-15 |
| HK1219130A1 (zh) | 2017-03-24 |
| KR102121369B1 (ko) | 2020-06-11 |
| JP6337020B2 (ja) | 2018-06-06 |
| CN105164535B (zh) | 2018-04-10 |
| LT2956772T (lt) | 2018-10-25 |
| KR20150118107A (ko) | 2015-10-21 |
| BR112015018213A8 (pt) | 2019-11-05 |
| PT2956772T (pt) | 2018-10-19 |
| DK2956772T3 (en) | 2018-08-13 |
| EP2956772A1 (en) | 2015-12-23 |
| HK1218954A1 (zh) | 2017-03-17 |
| CA2898111A1 (en) | 2014-08-21 |
| ZA201505386B (en) | 2021-09-29 |
| JP2016513253A (ja) | 2016-05-12 |
| US20150377885A1 (en) | 2015-12-31 |
| WO2014125164A1 (en) | 2014-08-21 |
| ES2683854T3 (es) | 2018-09-28 |
| CN105164535A (zh) | 2015-12-16 |
| EP2956772B1 (en) | 2018-05-30 |
| AU2014217753B2 (en) | 2018-07-05 |
| EP2956772A4 (en) | 2016-09-14 |
| AU2014217753A1 (en) | 2015-07-23 |
| PL2956772T3 (pl) | 2018-12-31 |
| SI2956772T1 (sl) | 2018-11-30 |
| US10247730B2 (en) | 2019-04-02 |
| BR112015018213B1 (pt) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015018213A2 (pt) | método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente | |
| BR112017007962A2 (pt) | método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit | |
| JP2016500110A5 (pt) | ||
| BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
| CY1118864T1 (el) | Μεθοδοι και συνθεσεις για μη επεμβατικη προγεννητικη διαγνωση εμβρυϊκων ανευπλοειδιων | |
| BR112017007965A2 (pt) | método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit | |
| ES2548508T3 (es) | Métodos de tratamiento de enfermedades | |
| BR112014020211A2 (pt) | métodos para analisar uma série ordenada por tempo de medições de um polímero, para estimar a presença, ausência ou quantidade de um polímero alvo, e para determinar uma alteração em um polímero, programa de computador, e, dispositivos de análise e de diagnóstico | |
| BR112013010023A2 (pt) | algoritimo aperfeiçoado para a detecção de diabetes | |
| BR112016028958A2 (pt) | método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento | |
| BR112016009099A2 (pt) | Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença | |
| BR112014008597A2 (pt) | sistema e método para determinação dos pontos q e j de um eletrocardiograma (ecg); um ou mais processadores; e mídia executável por computador não transitória | |
| BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
| BR112013000760A2 (pt) | método e aparelho para medir a espessura do tecido adiposo | |
| EA201270020A1 (ru) | Определение риска развития атеросклеротической болезни сердца | |
| BR112012031389A2 (pt) | método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue | |
| BR112014011818A2 (pt) | método para realizar ensaios de quantificação | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| EA201490946A1 (ru) | Способ количественной оценки лечения рака | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
| AR102037A1 (es) | Procesador y método para el procesamiento de una señal de audio por el uso del análisis truncado o las porciones de solapamiento de la ventana de síntesis | |
| BR112016002668A2 (pt) | métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares | |
| BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2014, OBSERVADAS AS CONDICOES LEGAIS |